Titre :
  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Auteur : Piccart-Gebhart, Martine ; Procter, Marion ; Leyland-Jones, Brian ; Goldhirsch, Aron ; Untch, M. ; Smith, Ian ; Gianni, L. ; Baselga, J ; Bell, Richard H ; Jackisch, C. ; Cameron, David A ; Dowsett, Mitch ; Barrios, CH ; Steger, G. ; Huang, C.-S. ; Andersson, M ; Inbar, M. ; Lichinitser, Michail ; Lang, Istvan ; Nitz, U. ; Iwata, Hiroji ; Thomssen, C. ; Lohrisch, C ; Suter, T. ; Rüschoff, Josef ; Sütö, T. ; Greatorex, V. ; Ward, David ; Straehle, Carolyn ; McFadden, E. ; Dolci, Stella ; Gelber, R D ; HERA study team
Informations sur la publication : The New England journal of medicine, 353, 16, (page 1659-1672)
Statut de publication : Publié, 2005-10
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Antibodies, Monoclonal -- adverse effects
Antibodies, Monoclonal -- therapeutic use
Antineoplastic Agents -- adverse effects
Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- mortality
Breast Neoplasms -- radiotherapy
Breast Neoplasms -- surgery
Chemotherapy, Adjuvant
Combined Modality Therapy
Disease-Free Survival
Female
Heart Diseases -- chemically induced
Humans
Middle Aged
Receptor, erbB-2 -- analysis
Recurrence
Survival Analysis
Note : Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0028-4793 
info:doi/10.1056/NEJMoa052306
info:pii/353/16/1659
info:pmid/16236737